{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"At least one TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"At least one treatment related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"At least one NPI-0052 related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"At least one grade ≥3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"At least one treatment related grade ≥3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"At least one NPI-0052 related grade ≥3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"At least one serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"At least one treatment related serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"At least one NPI-0052 related serious TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.\n\nTreatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship.","groups":[{"description":"Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles","id":"OG000","title":"MRZ 0.5 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 6.09 weeks.","title":"Number of Patients With Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}